MIP Technologies AB of Lund, Sweden, has entered into a collaboration with sanofi-aventis of Paris to develop molecularly imprinted polymers that will be used to analyze pharmacologically active peptides from plasma samples. The French company will have exclusive rights to use the polymer for analyzing proprietary peptides, while the Swedish company will retain the rights for its use in other applications.